Minerva Neurosciences (NASDAQ:NERV – Get Free Report) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.14) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. On average, analysts expect Minerva Neurosciences to post ($0.73) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year.
Minerva Neurosciences Stock Performance
Shares of Minerva Neurosciences stock opened at $2.32 on Monday. Minerva Neurosciences has a 1 year low of $1.96 and a 1 year high of $8.80. The firm’s 50-day simple moving average is $3.49 and its 200-day simple moving average is $4.88. The firm has a market cap of $110.78 million, a PE ratio of -0.08 and a beta of 0.09.
Analyst Ratings Changes
Several analysts recently weighed in on NERV shares. Wall Street Zen lowered Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Saturday. Zacks Research upgraded shares of Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a research note on Friday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Monday, September 21st. Finally, Jefferies Financial Group raised shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating and raised their target price for the stock from $7.50 to $10.00 in a report on Friday, August 14th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.33.
Get Our Latest Research Report on Minerva Neurosciences
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on conditions with significant unmet medical needs, including schizophrenia, depression and other psychiatric or neurological diseases.
Minerva’s lead product candidate has been roluperidone, an investigational therapy designed to address the negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression.
Featured Stories
- Five stocks we like better than Minerva Neurosciences
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
